HEOR & ACCESS CONSULTING LTD

Name

HEOR & ACCESS CONSULTING LTD

Legal name

HEOR & Access Consulting Ltd

Website

https://heoraccessconsulting.com

Company type

Private

Founded year

2023

Operating status

Operating

Ownership category

akta.pro rank

Product category

Pharma and biotech consulting (HEOR, HTA and market access)

NAICS

Management Consulting Services (54161)

SIC

Services-Management Consulting Services (8742)

akta.pro primary industry

Health Economics & Outcomes Research (HEOR) (HLAIAKAB)

akta.pro secondary industries

Payer & HTA Engagement (Reimbursement/Submissions) (HLAIAKAD), Real-World Evidence (RWE) & HEOR for Development (HLAIALAI)

Keywords

• HEOR consulting
• Market access advisory
• HTA strategy
• Pharma consulting
• Biotech evidence strategy

Headquarters

HQ city

Chertsey

HQ country

United Kingdom

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Marketing or Sales, Operations, Technology or R&D

Revenue model

1. Strategic HEOR & Market Access Consulting: Professional consulting engagements providing strategic and operational advisory services to pharmaceutical and biotech organizations. Engagement types include project-based consulting, fractional HEOR leadership, and interim leadership roles. Revenue is generated through professional service fees for advisory engagements.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels2 records

Core offering

HEOR & Access Consulting Ltd is an independent boutique consultancy providing strategic and operational advisory services in Health Economics and Outcomes Research (HEOR), Health Technology Assessment (HTA), and global market access to pharmaceutical and biotech organizations. Services include market access strategy, HTA and JCA readiness, integrated evidence generation, cost-effectiveness and value demonstration, COA/PRO strategy, and fractional HEOR leadership, delivered as bespoke project-based consulting engagements.

Product overview

HEOR & Access Consulting Ltd is an independent consulting firm offering strategic advisory services for pharmaceutical and biotech organizations. The company provides six core consulting service offerings: Global Market Access Strategy, HTA Strategy, JCA Readiness, Integrated Evidence Generation, HEOR, and COA/PRO Strategy. These services are delivered through Colette Mankowski, PhD, as a solo consultant practice, and are tailored to each client's specific asset, market and development stage needs. The firm specializes in evidence strategy, HTA navigation, and ensuring successful patient access outcomes for pharmaceutical innovations.

Differentiator

Problem solved

Functional benefit

Products and services

• Global Market Access Strategy Strategic advisory service for pharmaceutical and biotech clients to develop evidence-led market access strategies tailored to international healthcare systems, HTA frameworks and reimbursement requirements across Europe, the UK and other established markets.
• HTA Strategy Senior strategic advisory across national and international Health Technology Assessment pathways, covering evidence positioning, comparator and endpoint strategy, and strengthening reimbursement outcomes for pharmaceutical and biotech clients.
• JCA Readiness Advisory service preparing pharmaceutical and biotech assets, evidence packages and governance processes for the EU Joint Clinical Assessment under the EU HTA Regulation.
• Integrated Evidence Generation Design of integrated evidence generation strategies that align clinical, economic and patient-centred evidence across the development lifecycle to support regulatory, HTA and payer decision-making.
• HEOR Senior HEOR expertise combining strategic insight with technical delivery, including cost-effectiveness modelling, utility strategy, scenario analyses and value demonstration for pharmaceutical and biotech clients.
• COA/PRO Strategy Strategic advisory on Clinical Outcome Assessments (COA) and Patient-Reported Outcomes (PRO), including instrument selection, modification, validation and endpoint strategies that meet regulatory and HTA expectations.
• Fractional HEOR Leadership Senior interim leadership support for HEOR functions, offering organisations flexible access to experienced HEOR leadership without a permanent hire commitment.

Quantifiable outcome

• 120+ Access & HTA Projects completed
• +1 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators3 records

Recent moves4 records

Expansion highlights4 records

Direct peers

• Evidera: Evidera is a dedicated HEOR, RWE, and market access consultancy serving the same pharmaceutical and biotech clients as HEOR & Access Consulting. It is one of the most recognised specialist HEOR firms globally and the closest direct competitor in scope and customer base.
• Mtech Access: Mtech Access is a UK-based market access and HEOR consultancy providing strategic and tactical support to pharma and biotech. It is a direct peer given overlapping service offerings, UK base, and pharma/biotech customer segment.
• Valid Insight: Valid Insight is a UK-based market access, HEOR, and HTA consultancy serving pharma and biotech. It competes head-to-head with HEOR & Access Consulting on HTA strategy, value demonstration, and global market access advisory for similar mid-size pharma and emerging biotech clients.
• Double Helix Consulting: Double Helix Consulting is a UK-based market access and pricing consultancy serving pharma and medical device companies. It overlaps with HEOR & Access Consulting on payer strategy, value communication, and HTA advisory across European markets.
• Maple Health Group: Maple Health Group is a HEOR, market access, and evidence strategy consultancy supporting pharma and biotech clients. It is a direct peer in the HEOR/HTA advisory space with a similar boutique-to-mid-size operating model.

Broad incumbents

• ICON plc: ICON plc is a major global CRO offering HEOR and market access capabilities alongside its clinical research services. It is a broad incumbent that competes with HEOR & Access Consulting on enterprise pharma HEOR engagements, though HEOR is a smaller part of ICON's overall portfolio.
• IQVIA: IQVIA is the largest global CRO and healthcare data company offering HEOR, RWE, and market access services as part of its broad life sciences portfolio. It competes with HEOR & Access Consulting for enterprise pharma engagements but operates at vastly greater scale and with proprietary data assets.
• ZS Associates: ZS Associates is a global management consulting and professional services firm with a substantial pharma practice covering market access, HEOR, pricing, and commercial strategy. It serves the same pharma clients as HEOR & Access Consulting but at much larger scale and with broader scope.

Emerging players

• Wickenstones: Wickenstones is a UK-based specialist consultancy providing market access, pricing, and HEOR advisory to pharma and biotech. It is an emerging competitor with similar boutique positioning and overlapping UK/European client base.
• HERCULES Group: HERCULES is a European pharma consultancy offering HEOR, market access, and pricing services to pharma clients. It is an emerging competitor in the European HEOR advisory space with partial overlap on customer base and service offering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about HEOR & ACCESS CONSULTING LTD